Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

1.800 -0.040 (-2.17%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,440
Open 1.880
Bid (Size) 1.800 (20)
Ask (Size) 1.810 (2)
Prev. Close 1.840
Today's Range 1.800 - 1.880
52wk Range 1.680 - 14.83
Shares Outstanding 3,264,346
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Programs, Eyes Critical Trial Results in 2025–2026
Via Investor Brand Network
Exposures COVID-19
Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL
Via Investor Brand Network

Performance

YTD
-38.8%
-38.8%
1 Month
-3.7%
-3.7%
3 Month
-21.7%
-21.7%
6 Month
-45.6%
-45.6%
1 Year
-51.4%
-51.4%

More News

Read More
Therapeutic Target Shows Promise in Preventing Cancer Resulting from Chronic Gut Inflammation
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (SNGX) Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim
Via Investor Brand Network
New Swallowable Pill Provides Real-Time Gut Inflammation Tracking
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc.’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial
Via Investor Brand Network
Exposures COVID-19
Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results
Via Investor Brand Network
BioMedNewsBreaks — Zacks Research Issues Business Update as Soligenix Inc. (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial
Via Investor Brand Network
Exposures COVID-19
Study Links Higher Consumption of Ultra-Processed Foods to Heightened Psoriasis Risk
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc (SNGX) CEO Highlights Pipeline and Strategy in Latest BioMedWire Podcast Episode
Via Investor Brand Network
Exposures COVID-19
Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response
Via NewMediaWire
Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response
Via TheNewswire.com
Bacterial Meningitis Can Now Be Rapidly Diagnosed with New Test
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in Benzinga Video Highlighting 75% HyBryte™ Response Rate in FDA-Backed Skin Cancer Trial
Via Investor Brand Network
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
Via NewMediaWire
Exposures Product Safety
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
Via TheNewswire.com
Exposures Product Safety
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
Via Investor Brand Network
Topics Death
Exposures COVID-19 Death
Study Finds Link Between Childhood Maltreatment and Elevated Risk of Psoriasis, Rheumatoid Arthritis
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Study Shows the Gut is Key in Protecting the Brain After Stroke
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
Via Investor Brand Network

Frequently Asked Questions

Is Soligenix, Inc. - Common Stock publicly traded?
Yes, Soligenix, Inc. - Common Stock is publicly traded.
What exchange does Soligenix, Inc. - Common Stock trade on?
Soligenix, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Soligenix, Inc. - Common Stock?
The ticker symbol for Soligenix, Inc. - Common Stock is SNGX on the Nasdaq Stock Market
What is the current price of Soligenix, Inc. - Common Stock?
The current price of Soligenix, Inc. - Common Stock is 1.800
When was Soligenix, Inc. - Common Stock last traded?
The last trade of Soligenix, Inc. - Common Stock was at 06/13/25 03:59 PM ET
What is the market capitalization of Soligenix, Inc. - Common Stock?
The market capitalization of Soligenix, Inc. - Common Stock is 5.88M
How many shares of Soligenix, Inc. - Common Stock are outstanding?
Soligenix, Inc. - Common Stock has 6M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.